Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
mRNA-4106 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 (Dose Escalation): mRNA-4106 Alone | EXPERIMENTAL | Participants will receive mRNA-4106 at a test dose as monotherapy. |
| Arm 2 (Dose Escalation): mRNA-4200 Alone and in Combination with Pembrolizumab | EXPERIMENTAL | Participants will receive mRNA-4200 as monotherapy, followed by mRNA-4200 in combination with pembrolizumab, and continuation of pembrolizumab alone. |
| Name | Type | Description |
|---|---|---|
| mRNA-4106 | BIOLOGICAL | Intramuscular injection |
| Pembrolizumab | BIOLOGICAL | Intravenous infusion |
| mRNA-4200 | BIOLOGICAL | Intramuscular injection |
Key Inclusion Criteria: * Arm 1: Histologically confirmed advanced or metastatic cancer (melanoma, non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), esophageal carcinoma, head and neck squamous cell carcinoma (HNSCC), urinary bladder cancer (UBC), colon/rectal adenocarcinomas, gas...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
mRNA-4106 is an investigational monoclonal antibody being developed for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied as a single agent and in combination with other anti-cancer agents.
mRNA-4106 is being developed by Moderna, Inc., a biotechnology company traded on the NASDAQ under the ticker symbol MRNA. The company is conducting a Phase 1 clinical trial to evaluate the safety and efficacy of mRNA-4106 in participants with advanced solid tumors.
mRNA-4106 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The ongoing Phase 1 trial is actively recruiting participants with advanced solid tumors in the United States.
mRNA-4106 is being evaluated in a single Phase 1 clinical trial registered as NCT06880549. This study is recruiting 42 participants with advanced solid tumors and is being conducted in the United States. The trial is testing mRNA-4106 alone or in combination with other anti-cancer agents.
No, mRNA-4106 and mRNA-4200 are distinct investigational drugs. However, both are being studied in the same Phase 1 clinical trial, NCT06880549, which evaluates each drug alone or in combination with other anti-cancer agents in participants with advanced solid tumors.